191 related articles for article (PubMed ID: 27620315)
1. Prognostic role of tissue transglutaminase 2 in colon carcinoma.
Fernández-Aceñero MJ; Torres S; Garcia-Palmero I; Díaz Del Arco C; Casal JI
Virchows Arch; 2016 Dec; 469(6):611-619. PubMed ID: 27620315
[TBL] [Abstract][Full Text] [Related]
2. Transglutaminase 2 overexpression in tumor stroma identifies invasive ductal carcinomas of breast at high risk of recurrence.
Assi J; Srivastava G; Matta A; Chang MC; Walfish PG; Ralhan R
PLoS One; 2013; 8(9):e74437. PubMed ID: 24058567
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of Transglutaminase 2 in non-small cell lung cancer patients.
Chihong Z; Yutian L; Danying W; Ruibin J; Huaying S; Linhui G; Jianguo F
Oncotarget; 2017 Jul; 8(28):45577-45584. PubMed ID: 28715877
[TBL] [Abstract][Full Text] [Related]
4. The increased transglutaminase 2 expression levels during initial tumorigenesis predict increased risk of metastasis and decreased disease-free and cancer-specific survivals in renal cell carcinoma.
Erdem S; Yegen G; Telci D; Yildiz I; Tefik T; Issever H; Kilicaslan I; Sanli O
World J Urol; 2015 Oct; 33(10):1553-60. PubMed ID: 25515319
[TBL] [Abstract][Full Text] [Related]
5. Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells.
Verma A; Guha S; Wang H; Fok JY; Koul D; Abbruzzese J; Mehta K
Clin Cancer Res; 2008 Apr; 14(7):1997-2005. PubMed ID: 18381937
[TBL] [Abstract][Full Text] [Related]
6. Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target.
Agnihotri N; Mehta K
Amino Acids; 2017 Mar; 49(3):425-439. PubMed ID: 27562794
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer.
Mehta K; Fok J; Miller FR; Koul D; Sahin AA
Clin Cancer Res; 2004 Dec; 10(23):8068-76. PubMed ID: 15585642
[TBL] [Abstract][Full Text] [Related]
8. Tissue transglutaminase induces Epithelial-Mesenchymal-Transition and the acquisition of stem cell like characteristics in colorectal cancer cells.
Ayinde O; Wang Z; Griffin M
Oncotarget; 2017 Mar; 8(12):20025-20041. PubMed ID: 28223538
[TBL] [Abstract][Full Text] [Related]
9. Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway.
Wang X; Yu Z; Zhou Q; Wu X; Chen X; Li J; Zhu Z; Liu B; Su L
Oncotarget; 2016 Feb; 7(6):7066-79. PubMed ID: 26771235
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
11. The role of tissue transglutaminase (TG2) in regulating the tumour progression of the mouse colon carcinoma CT26.
Kotsakis P; Wang Z; Collighan RJ; Griffin M
Amino Acids; 2011 Oct; 41(4):909-21. PubMed ID: 21046178
[TBL] [Abstract][Full Text] [Related]
12. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C
Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
[TBL] [Abstract][Full Text] [Related]
13. Activation of transglutaminase type 2 for aortic wall protection in a rat abdominal aortic aneurysm formation.
Munezane T; Hasegawa T; Suritala ; Tanaka A; Okada K; Okita Y
J Vasc Surg; 2010 Oct; 52(4):967-74. PubMed ID: 20615646
[TBL] [Abstract][Full Text] [Related]
14. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
15. Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathways.
Kumar S; Donti TR; Agnihotri N; Mehta K
Int J Cancer; 2014 Jun; 134(12):2798-807. PubMed ID: 24477458
[TBL] [Abstract][Full Text] [Related]
16. Tissue transglutaminase-mediated chemoresistance in cancer cells.
Verma A; Mehta K
Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
[TBL] [Abstract][Full Text] [Related]
17. Stromal VCAN expression as a potential prognostic biomarker for disease recurrence in stage II-III colon cancer.
Chida S; Okayama H; Noda M; Saito K; Nakajima T; Aoto K; Hayase S; Momma T; Ohki S; Kono K; Takenoshita S
Carcinogenesis; 2016 Sep; 37(9):878-887. PubMed ID: 27287872
[TBL] [Abstract][Full Text] [Related]
18. Transglutaminase 2: a multi-functional protein in multiple subcellular compartments.
Park D; Choi SS; Ha KS
Amino Acids; 2010 Aug; 39(3):619-31. PubMed ID: 20148342
[TBL] [Abstract][Full Text] [Related]
19. Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer.
Mehta K; Kumar A; Kim HI
Biochem Pharmacol; 2010 Dec; 80(12):1921-9. PubMed ID: 20599779
[TBL] [Abstract][Full Text] [Related]
20. High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients.
Coebergh van den Braak RRJ; Sieuwerts AM; Kandimalla R; Lalmahomed ZS; Bril SI; van Galen A; Smid M; Biermann K; van Krieken JHJM; Kloosterman WP; Foekens JA; Goel A; Martens JWM; IJzermans JNM;
PLoS One; 2017; 12(9):e0185607. PubMed ID: 28957395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
